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Abstract: A new route to 3-(4-arylmethylamino)butyl-5-arylidene-2-thioxo-1,3-thiazolidine-
4-one 9 was developed in six steps from commercial 1,4-diaminobutane 1 as starting 
material. The key step of this multi-step synthesis involved a solution phase “one-pot  
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two-steps” approach assisted by microwave dielectric from N-(arylmethyl)butane-1,4-diamine 
hydrochloride 6a–f (as source of the first point diversity) and commercial bis-(carboxymethyl)-
trithiocarbonate reagent 7 for construction of the rhodanine platform. This platform was 
immediately functionalized by Knoevenagel condensation under microwave irradiation 
with a series of aromatic aldehydes 3 as second point of diversity. These new compounds 
were prepared in moderate to good yields and the fourteen synthetic products 9a–n have 
been obtained with a Z-geometry about their exocyclic double bond. These new 5-arylidene 
rhodanines derivatives 9a–n were tested for their kinase inhibitory potencies against four 
protein kinases: Human cyclin-dependent kinase 5-p25, HsCDK5-p25; porcine Glycogen 
Synthase Kinase-3, GSK-3α/β; porcine Casein Kinase 1, SsCK1 and human HsHaspin. 
They have also been evaluated for their in vitro inhibition of cell proliferation (HuH7 D12, 
Caco 2, MDA-MB 231, HCT 116, PC3, NCI-H727, HaCat and fibroblasts). Among of all 
these compounds, 9j presented selective micromolar inhibition activity on SsCK1 and 9i 
exhibited antitumor activities in the HuH7 D12, MDA-MBD231 cell lines. 
Keywords: one-pot two-steps; Knoevenagel condensation; 5-arylidene rhodanine; protein 
kinase; inhibitor; SsCK1; HsCDK5-p25; cell lines; Alzheimer’s disease; cancer 
 
1. Introduction 
During the last decades, the five-membered heterocycle rings (FMHRs) are considered “privileged 
scaffolds” in medicinal chemistry [1]. Among the five-membered heterocycle rings, the 5-arylidene-2-
thioxo-1,3-thiazolidine-4-ones or 5-arylidene rhodanine derivatives represented particularly privileged 
moieties in drug discovery because they have an inherent tendency for biological activity [2], such as 
DDX3 inhibitor for HIV replication [3], as potent and selective inhibitors of the “atypical” dual-specificity 
phosphatase (DSP) family member-JNK-stimulating phosphatase-1 (JSP-1) [4], as pancreatic cholesterol 
esterase (CEase) inhibitor [5] with IC50 values ranging from 1.44 to 85 μM. To discover chemical probes 
to further understand the function of human DNA polymerase λ in cancer, an inhibitor high-throughput 
screening (HTS) using SYBR® Green-base assay [6] revealed that three 5-arylidene-2-thioxo- 
1,3-thiazolidine-4-ones were identified as strong inhibitors. A new series of D-glutamic acid-base 
Escherichia coli MurD inhibitors incorporating the 5-arylidene rhodanine scaffold have been designed, 
synthesized and evaluated [7]. Substituted 5-arylidene-2-thioxo-1,3-thiazolidine-4-ones were able to 
inhibit HIV replication in MT-4 cells at low micromolar concentration with an appreciable selectivity 
index and are good scaffolds for the development of novel HIV-1 integrase inhibitors [8]. Recently, a 
family of 5-arylalkylidene rhodanine derivatives presented antiviral activity against chikungunya virus 
(LR2006_OPY1) in Vero cell culture by cytopathic effect CPE reduction assay [9]. For Alzheimer’s 
disease, the FMHRs derived from 5-arylidene-2-thioxo-1,3-thiazolidine-4-ones have been described  
for amyloid polypeptide fibril formation [10], regulation of Cathepsin D immuno-reactivity in the senile 
plaques [11] and inhibition of tau aggregation [12]. 
Protein kinases represent an important class of enzymes that play an important role in the regulation 
of various processes. These enzymes catalyze protein-phosphorylation on serine, threonine and tyrosine 
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residues, which are frequently deregulated in human diseases. Only the 518 human kinases have been 
investigated as potential therapeutic targets [13]. Consequently, the search of protein-kinase inhibitors 
represented interesting targets in the pharmaceutical industry for new therapeutic agents. Over the past 
decade, our research group have investigated the chemical development of five-membered heterocycle 
rings derived from marine alkaloid as low-molecular weight-inhibitors of dual specificity, tyrosine 
phosphorylation-regulated kinases (DYRKs) and CLKs (cdc2-like kinases) [14–16], two families of 
kinases involved in various diseases including Alzheimer’s disease (AD) [17], and also cancer [18–20]. 
Continuing in the effort to identify new DYRK inhibitors, particularly DYRK1A, we continued  
to explore successively the synthesis of N,Nʹ-bis-(5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl) 
diamines [21], N,Nʹ-bis-(5-arylidene-4-oxo-4,5-dihydrothiazolidine-2-yl)aminopropylpiperazines [22] and 
finally unsymmetrical linked bis-5-arylidene-rhodanine derivatives linked in N-3 position [23] as potential 
kinases inhibitors (Figure 1). Among the three series of symmetrical or unsymmetrical N,Nʹ-diamines 
bearing various platforms (imidazolidine-4-one or 2-thioxo-1,3-thiazolidine-4-one moieties), only one 
of these compounds has shown nanomolar inhibition potency (IC50 40 nM) towards DYRK1A. Owing to 
the fact that none of the unsymmetrical linked bis-5-arylidene rhodanines presented a significant activity 
against representative tumoral cell lines, we decided to change one of the two heterocyclic platforms by 
various (arylmethyl)aminobutyl moieties grafted on N-3 position of 5-arylidene-rhodanine derivatives 
in order to obtain significant potential biological activities on tumoral cell lines and effects on some 
protein kinases (HsCDK5-p25, SsGSK3α/β, SsCK1 and HsHaspin). Herein, we present the building of 
this 3-(4-arylmethylamino)butyl-5-arylidene-rhodanine library in which the 5-arylidene-2-thioxo-1,3-
thiazolidine-4-one moiety was mostly carried out under microwave irradiation [24] and the biological 
activities of these compounds. 
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Figure 1. Symmetrical linked bis-5-arylidene imidazoline-4-ones, symmetrical linked  
bis-5-arylidene-1,3-thiazoline-4-ones and unsymmetrical linked bis-5-arylidene rhodanines 
derivatives (as inhibitors of the proteine kinase DYRK1A or against cell proliferation on 
cell tumor lines) identified and developed in our group. 
2. Results and Discussion 
2.1. Chemistry 
Access to the planned 3-(4-arylphenylamino)butyl-5-arylidene-2-thioxo-1,3-thiazolidine-4-ones 9 is 
outlined in Scheme 1. For this study, we selected a diamino linker 1 with a butyl chain in order to obtain 
a good molecular flexibility between the 4-arylmethyl moiety and the 2-thioxo-1,3-thiazolidine-4-one 
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platform. A molecule with the lowest number of carbons for the diamino linker is more conformationally 
restrained [25]. The 1,4-diamino-butane linker 1 was treated with di-tert-butyldicarbonate (Boc2O) in 
1,4-dioxane at room temperature to afford mainly the mono-N-Boc protected amine 2 in good yield 
(84%) [26]. To obtain a sufficient number of compounds suitable for a preliminary biological screening, 
we privileged the transformation of N-Boc-1,4-diamino-butane 2 into mono protected N-arylmethyl 
diamine 5 by reductive amination in two steps. The (4-arylmethylamino)butyl chain appended on the 
N-3 position of the 2-thioxo-1,3-thiazolidine-4-one platform represent the first point of diversity for the 
desired target compounds 9. Preparation of 4 was easily realized by reaction between of appropriate 
arylaldehyde 3a–f with N-Boc diamine 2 in the presence of molecular sieves 3Å and, the condensation 
was conducted in a solution of diethyl ether Et2O at room temperature during 24 h. Then, transformation 
of arylaldimines 4 into mono protected N-arylmethyl diamines 5 could be readily accomplished in 
good yields (85% to 98%) using NaBH4 (5 equiv.) in MeOH at 50 °C during 24 h. For the cleavage of 
N-Boc group, the use of trifluoroacetic acid in dichloromethane is often efficient, but in our case, we 
observed the formation of impurities resulting from uncontrolled degradation of 5 in this strong acidic 
media. We thus preferred to use a more classical and practical approach by using a solution of  
6M HCl. The deprotection was conducted in 1,4-dioxane at room temperature after 4 h of reaction time. 
As can be seen from the data presented in Table 1, the N-(arylmethyl)butane-1,4-diamine hydrochloride 
6a–f were efficiently prepared with electron-rich and electron-poor aldehydes 3a–f in yields ranging 
from 72% to 98%. 
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Scheme 1. Route used for the preparation of 3-(4-arylphenylamino)butyl-5-arylidene-2-
thioxo-1,3-thiazolidine-4-ones 9 via the “one-pot two-steps” reaction under microwave. 
Reagents and reaction conditions: (i) (t-BuO2C)2O, 1,4-dioxane, 25 °C, 24 h. (ii) 3 1 
equiv., molecular sieve 3Å, Et2O, 25 °C, 16 h. (iii) NaBH4 5 equiv., MeOH, 50 °C, 24 h. 
(iv) HCl 6 M, 1,4-dioxane, 25 °C, 4 h. (v) 6 1 equiv., 7 1 equiv., Et3N 2 or 3 equiv., DME, 
MWI, 90 °C, 15 or 30 min. (vi) 3 1 equiv., MWI, 110 °C, 15 or 30 min. 
With the desired salts 6 in hand, we wished to examine the construction of the 2-thioxo-1,3-
thiazolidine-4-one platform followed by Knoevenagel condensation using arylaldehyde 3 under 
microwave irradiation for installation of the 5-arylidene moiety. The choice of arylaldehydes 3 in 
Knoevenagel condensation represent, in fact, the second point of diversity in the final structure of the 
targeted compounds 9. In a previous work issued from our laboratory [23], we have developed a  
“one-pot two-steps” method under microwave irradiation, which was applied for the synthesis of 
unsymmetrical linked bis-arylidene rhodanines from symmetric diamines. 
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Table 1. Results for the preparation of compounds 2, 4, 5, 6 and 9. 
Compound 
Starting 
Product 
Reaction Conditions under MWI a 
Yield b 
(%) 
Starting 
Product 6 
Number of 
equiv. for Et3N 
Reaction Time 
for 8 c (min) 
Reaction Time for 
Condensation d (min) 
2 - - - - - 84 
4a 3a - - - - 97 
4b 3b - - - - 99 
4c 3c - - - - 98 
4d 3d - - - - 98 
4e 3e - - - - 98 
4f 3f - - - - 99 
5a 4a - - - - 93 
5b 4b - - - - 99 
5c 4c - - - - 85 
5d 4c - - - - 90 
5e 4e - - - - 97 
5f 4f - - - - 98 
6a 5a - - - - 84 
6b 5b - - - - 97 
6c 5c - - - - 98 
6d 5d - - - - 98 
6e 5e - - - - 72 
6f 5f - - - - 92 
9a 3e 6b 3 30  30 10 
9b 3b 6b 3 30 30 6 
9c 3f 6b 3 30  30 5 
9d 3g 6b 3 30 30 30 
9e 3e 6d 3 15  15 21 
9f 3f 6d 3 15 15 9 
9g 3d 6d 3 30 30 5 
9h 3e 6e 2 15 15 59 
9i 3f 6e 2 15 15 59 
9j 3h 6e 2 15 15 34 
9k 3g 6e 3 30 30 46 
9l 3e 6f 3 15 15 15 
9m 3f 6f 3 15 15 7 
9n 3g 6f 3 30 30 34 
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Notes: a Reaction realized in a tube (sealed with a snap cap) under microwave irradiation (μω) with the 
Monowave® 300 Anton-Paar reactor. b Isolated yield. c Reaction temperature: 90 °C for the preparation of 8 
(1st period of microwave irradiation). d Reaction temperature: 110 °C for condensation reaction after addition 
of 3 (2nd period of microwave irradiation). 
Application of this methodology, based on a “modified Holmberg method”, first involved, in our 
case, the reaction of the commercial bis-(carboxymethyl)-trithiocarbonate reagent 7 with the synthesized 
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N-(arylmethyl)butane-1,4-diamine hydrochloride 6 to afford the intermediate 8 and secondly, Knoevenagel 
condensation to produce the desired 5-arylidene rhodanines 9. This “one-pot two-steps” methodology 
was realized under microwave dielectric heating because the use of commercial scientific laboratory 
microwave apparatus favoured higher product yields and significant rate enhancements compared to 
reactions which run with conventional heating (i.e., in oil bath) [27]. After several experiments, 
optimal reaction conditions for this “one-pot two-steps” synthesis involved reaction of a stoichiometric 
mixture of N-(arylmethyl)butane-1,4-diamine hydrochloride 6 and commercial reagent 7 solubilized in 
dimethoxyethane with one or two equivalents of triethylamine. This starting reaction mixture was 
placed in a commercial glass tube closed with a snap cap and was irradiated with appropriate reaction 
time (15 or 30 min.) at 90 °C. After this first period of microwave irradiation followed by a cooling 
down to room temperature, aromatic aldehyde 3 was directly added to the crude suspension and was 
submitted again to microwave dielectric heating at 110 °C during 15 or 30 min for condensation. 
The desired compound 9 was obtained as precipitate after addition of methanol in the solventless 
crude reaction mixture (after elimination of the volatile compounds in vacuo) and triturated, followed by 
successive washings with deionized water, ethanol, ether and finally was recrystallized from absolute 
EtOH to increase the quality of the precipitated product 9. A set of 14 pure compounds 9a–n was 
prepared in 5%–59% yield (Table 1) and all the products 9 were characterized by 1H-, 13C-NMR and 
HRMS before entering the biological tests. For the exocyclic double bond (CH=C) in C-5 position of all 
the 3-(4-arylmethylamino)butyl-2-thioxo-1,3-thiazolidine-4-one 9a–n, it’s possible in theory to observe 
E- and/or Z-geometrical isomers. Examination of their 1H-NMR spectra in DMSO-d6 showed only one 
signal for the methylene proton (CH=) in the range 7.54–7.74 ppm at lower field values than those 
expected for the E-isomers, which indicates that all the compounds 9a–n have the Z-configuration due to 
the high degree of thermodynamic stability of this isomer [28,29]. In 13C-NMR, the signal of C-5 (C=) 
appears in the range 120.0–127.5 ppm, and we also observed only one signal for the exocyclic methylene 
proton (134.6 < δCH= < 135.9 ppm) that confirmed the presence of only the Z-geometrical isomer for 
the targeted compounds 9a–n. 
2.2. Biology 
As an initial effort to investigate their in vitro bioactivity, the new synthesized 3-(4-arylmethylamino) 
butyl-2-thioxo-1,3-thiazolidine-4-one 9a–n and also their precursors 6a–f were evaluated for their  
in vitro inhibition of cell proliferation. For this study, we used a panel of seven representative tumoral 
cell lines, namely HuH7 D12 (differential hepato cellular carcinoma), Caco 2 (differentiating colorectal 
adenocarcinoma), MDA-MBD231 (prostate carcinoma), HCT 116 (actively proliferating colorectal 
adenocarcinoma), PC3 (prostate carcinoma), NCI-H727 (lung carcinoma), HaCat keratinocyte and, 
diploid skin fibroblasts as normal cell lines for control. Roscovitine, Doxorubicine and Taxol were also 
used as positive controls and their IC50 values are compared with those obtained for compounds 6 and 9. 
Results of the in vitro antiproliferative data activity are reported in Table 2. None of the N-(arylmethyl) 
butane-1,4-diamines hydrochloride 6a–f presented a significant activity against the seven representative 
tumoral cell lines. For the other compounds 9, the most active compound was clearly 9i (Figure 2) and 
exhibited antitumor activities in the HuH7 D12, MDA-MBD231 and HaCat cell lines with IC50 values 
lower than 10 μM (HuH7 D12 and MDA-MBD231: IC50 9 μM) and did not inhibit the growth of normal 
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fibroblasts (IC50 > 25 μM). In addition, compounds 9d, 9h, 9j and 9n presented moderate antitumor 
activities (IC50 10–17 μM) in all cell lines of the panel but without selectivity. 
Table 2. Antiproliferative activity of compounds 6(a–e) and 9(a–n) on six representative 
tumor cell lines. 
Compound 
% of Survival a and IC50 (μM) of Selected Compounds b 
Huh7 D12 Caco 2 MDA-MB231 HCT 116 PC3 NCI-H727 HaCat Fibroblasts 
6a 102 114 104 112 100 97 97 93 
6b 107 114 100 112 100 86 106 100 
6c 82 93 102 98 96 100 80 84 
6d 107 111 99 111 98 92 96 93 
6e 91 106 102 102 96 98 96 93 
6f 88 109 99 96 97 92 94 105 
9a 85 109 100 109 92 104 103 104 
9b 105 108 97 102 99 90 104 167 
9c 88 93 92 97 97 95 101 102 
9d 7 (10) 23 (15) 15 (11) 1 (10) 41 (17) 11 (10) 2 (10) 29 (>25) 
9e 74 97 97 99 85 102 86 122 
9f 102 110 98 113 98 96 100 134 
9g 111 117 104 118 98 95 110 100 
9h 7 (10) 42 (14) 49 (10) 65 (13) 51 (13) 43 (>25) 10 (10) 80 (>25) 
9i 5 (9) 17 (13) 17 (9) 8 (14) 39 (14) 9 (11) 6 (8) 54 (>25) 
9j 22 (11) 41 (27) 42 (19) 40 (22) 38 (19) 33 (19) 21 (13) 77 (>25) 
9k 72 98 92 98 83 96 80 84 
9l 90 105 98 106 93 96 95 128 
9m 97 107 99 103 96 98 94 149 
9n 41 (15) 28 (16) 55 (15) 52 (21) 61 (19) 63 (17) 48 (15) 86 (>25) 
Roscovitine 21 (15) 3 (15) 21 (12 10 (9) 24 (13) 30 (43) 6 (11) 53 (125) 
Doxorubicine 63 (0.03) 43 (0.03) 82 (0.01) 22 (0.03) 34 65 88 (0.02) 74 (>0.25) 
Taxol 36 (0.003) 29 (0.04) 41 (0.04) 9 (<0.001) 35 (<0.001) 59 11 (0.001) 76 (>25) 
DMSO 100 (>25) 100 (>25) 100 (>25) 100 (>25) 100 (>25) 100 (>25) 100 (>25) 100 (>25) 
Notes: a Percentage of survival measured at 25 μM (after 48 h using a single dose, triplicate). b IC50 values in 
brackets are expressed in μM and are the average of three assays, standard error ± 0.5 μM. 
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Figure 2. Structure of compounds 9d, 9(h–j) and 9n, which are active against protein 
kinases and/or tumor cell lines. 
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Then, we evaluated the intermediates salts 6a–f and fourteen final compounds 9a–n on four protein 
kinases: HsCDK5-p25 (cyclin-dependant kinase 5-p25), SsGSK-3α/β (glycogen synthase kinase-3α/β) 
SsCK1δ/ε (Caseine kinase 1) and HsHaspin as an essential mitotic kinase [30]. All assays were run in the 
presence of 15 μM of ATP and appropriate substrates. IC50 values were determined from dose-response 
curves. Concerning the library of the fourteen (5Z) 3-(4-arylmethylamino)butyl-5-arylidene-2-thioxo-
1,3-thiazolidine-4-ones 9a–n and also the six diamines salts 6a–f, the results are given in Table 3. 
Among all the products, the main part of their inhibition activity was focused on two proteins kinases 
(SsCK1 and HsCDK5-p25) for four products, which exhibited inhibitory activity in the micromolar 
range (SsCK1: 1.4 μM < IC50 < 6.6 μM; HsCDK5-p25: IC50 1.2 μM). For the compound 9j and 9n, we 
observed micromolar inhibition activity on SsCK1 (IC50 values for 9j: 1.4 μM and 9n: 2 μM) with 
good selectivity. It is interesting to note that these two compounds are respectively substituted with  
an hydroxyl function on para-position of the 5-arylidene moiety and also with a similar bulky group 
(1,3-benzodioxol-5-yl for 9j and 2,3-dihydro-benzo[1,4]dioxin-6-yl for 9n) on the arylmethylamino 
moiety grafted on the N-3 butyl chain. On the contrary, the presence of 1,3-benzodioxol-5-yl (for 9h) 
or 2,3-dihydro-benzo[1,4]dioxin-6-yl moiety (for 9i) in the 5-arylidene group induced a moderate loss 
of inhibition activity for SsCK1 (IC50 for 9h: 6.6 μM and 9i: 5.4 μM) associated with micromolar 
affinity for HsCDK5-p25 (IC50 for 9h: 1.1 μM and 9i: 1.3 μM). Compound 9i presented also inhibition 
proliferation activity on Huh7 D12, MDA-MBD231 cell lines and is inactive against normal fibroblasts. 
Table 3. Effects of the compounds 6a–f and 9a–n on the catalytic activity of four purified 
protein kinases a. 
Compound HsCDK5/p25 SsGSK-3α/β SsCK1δ/ε HsHaspin 
6a–f >10 >10 >10 >10 
9a–g >10 >10 >10 >10 
9h 1.1 >10 6.6 >10 
9i 1.3 >10 5.1 >10 
9j >10 >10 1.4 >10 
9k–m >10 >10 >10 >10 
9n 10 >10 2 >10 
Note: a Compounds were tested at various concentrations on each kinase as described in Experimental Section. 
IC50 values, calculated from the dose-response curves, are reported in μM > 10, inhibitory but IC50 > 10 μM. 
3. Experimental Section 
3.1. Chemistry Section 
3.1.1. General Section 
Melting points were determined on a Kofler melting point apparatus and were uncorrected. Thin-layer 
chromatography (TLC) was accomplished on 0.2-mm precoated plates of silica gel 60 F-254 (Merck, 
Fontenay-sous-Bois, France). Visualization was made with ultraviolet light (254 and 365 nm) or with a 
fluorescence indicator. 1H-NMR spectra were recorded on BRUKER AC 300 P (300 MHz) spectrometer, 
13C-NMR spectra on a BRUKER AC 300 P (75 MHz) spectrometer. Chemical shifts are expressed in 
parts per million downfield from tetramethylsilane as an internal standard. Data are given in the 
Molecules 2015, 20 12420 
 
 
following order: δ value, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), 
number of protons, coupling constants J is given in Hertz. The mass spectra (HRMS) were taken 
respectively on a MS/MS ZABSpec Tof Micromass (EBE TOF geometry) at an ionizing potential of  
8 eV and on a VARIAN MAT 311 at an ionizing potential of 70 eV in the Centre Régional de Mesures 
Physiques de l’Ouest (CRMPO, Rennes, France). Reactions under microwave irradiations were realized 
in the Anton Paar Monowave 300® microwave reactor (Anton-Paar, Courtaboeuf, France) using 
borosilicate glass vials of 10 mL equipped with snap caps (at the end of the irradiation, cooling reaction 
was realized by compressed air). The microwave instrument consists of a continuous focused microwave 
power output from 0 to 800 W for this Monowave 300® apparatus. All the experiments in the microwave 
reactor were performed using a stirring option. The target temperature was reached with a ramp of  
5 min and the chosen microwave power stayed constant to hold the mixture at this temperature. The 
reaction temperature is monitored using calibrated infrared sensor and the reaction time included the 
ramp period. The microwave irradiation parameters (power and temperature) were monitored by the 
Monowave software package of the Monowave 300® microwave reactor. Solvents were evaporated 
with a BUCHI rotary evaporator. All reagents and solvents were purchased from Acros, Sigma-Aldrich 
Chimie (Saint-Quentin Fallavier, France), TCI France and Fluka France and were used without  
further purification. 
tert-Butyl (4-aminobutyl)carbamate (2). In a 250 mL two-necked round-bottomed flask, provided  
with magnetic stirrer and condenser, commercial 1,4-diaminobutane 1 (14.3 mL, 12.5 g, 0.14 mol) was 
solubilized in 69 mL of 1,4-dioxane at room temperature. To this mixture was added dropwise a solution 
of commercial di-tert-butyldicarbonate (6.5 g, 30 mmol) in 1,4-dioxane (85 mL) over a period of 3 h. 
After vigorous stirring at 25 °C during a 12 h period, the volatile compounds of the reaction mixture 
were eliminated in vacuo and into the crude reaction mixture was poured 150 mL of deionized water. 
The mixture was extracted with methylene chloride (5 × 50 mL), organic phases were collected and dried 
over magnesium sulfate. The filtrate was concentrated in a rotary evaporator under reduced pressure and 
was dried under high vacuum (10−2 Torr) at 25 °C for 10 min. The desired carbamate 2 (1.58 g) was 
obtained as a colourless mobile oil in 84% yield and was further used without purification. 1H-NMR 
(DMSO-d6) δ: 1.34 (s, 9H, Me3CO); 1.40 (m, 4H, CH2); 2.61 (t, 2H, J = 6.7 Hz, CH2); 3.02 (m, 2H, 
CH2NH); 4.93 (br s, 2H, NH2); 5.71 (br s, 1H, NH). 13C-NMR (DMSO-d6) δ: 27.2 (CH2); 28.4 
(OC(CH3)3); 29.5 (CH2); 40.2 (CH2); 41.1 (CH2); 78.9 (OC(CH3)3); 156.1 (C=O). HRMS, m/z: 
189.1600 found (calculated for C9H21N2O2 [M + H]+ requires 189.1603). 
3.1.2. Standard Procedure for the Preparation of Aldimines 4a–f from tert-Butyl (4-aminobutyl) 
Carbamate 2 and Aromatic Aldehyde 3a–f 
In a 100 mL two-necked round-bottomed flask, provided with magnetic stirrer and condenser, 
containing a solution of tert-butyl (4-aminobutyl)carbamate 2 (1.97 g, 10.5 mmol) in anhydrous ether 
(50 mL) was added dropwise during 30 min, a suspension of commercial aldehyde (10 mmol) in anhydrous 
ether (30 mL) and molecular sieves (2 g, 3 Å, 8–12 mesh). The crude reaction mixture is stirred vigorously 
for 16 h at room temperature until the disappearance of aromatic aldehyde 3 controlled by thin-layer 
chromatography on 0.2-mm precoated plates of silica gel 60 F-254 (Merck). The crude reaction mixture 
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was filtered on filter paper and then concentrated in a rotary evaporator under reduced pressure. The 
crude residue was dried under high vacuum (10−2 Torr) at 25 °C for 10 min. The desired aldimine 4 was 
obtained as yellowish viscous oil and was further used without purification. 
[4-(Benzylidene-amino)-butyl]-carbamic acid tert-butyl ester (4a). Compound 4a was prepared in 97% 
yield (2.68 g) from benzaldehyde 3a (1.06 g, 10 mmol) according to the standard procedure as yellowish 
viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.40–1.48 (m, 2H, CH2, H-2); 1.54–1.62 (m, 
2H, CH2, H-3); 2.96 (q, 2H, J = 6.8 Hz, CH2NH, H-1); 3.55 (t, 2H, J = 6.8 Hz, CH2N=, H-4); 6.79–6.83 
(br s, 1H, NH); 7.41–7.46 (m, 3H, H-3ʹ, H-4ʹ, H-5ʹ, Ar); 7.71–7.75 (m, 2H, H-2ʹ, H-6ʹ, Ar); 8.32 (s, 1H, 
N=CH). 13C-NMR (DMSO-d6) δ: 27.3 (C-2); 27.8 (C-3); 28.2 (OC(CH3)3); 39.6 (C-1); 60.1 (C-4); 77.2 
(OC(CH3)3); 127.7 (C-2ʹ, C-6ʹ, Ar); 128.5 (C-3ʹ, C-5ʹ, Ar); 130.4 (C-4ʹ, Ar); 136.1 (C-1ʹ, Ar); 155.5 
(C=O); 160.5 (N=CH). 
{4-[(4-Methoxy-benzylidene)-amino]-butyl}-carbamic acid tert-butyl ester (4b). Compound 4b was 
prepared in 99% yield (3.03 g) from 4-methoxybenzaldehyde 3b (1.36 g, 10 mmol) according to the 
standard procedure as yellowish viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.32–1.46 
(m, 2H, CH2, H-2); 1.52–1.61 (m, 2H, CH2, H-3); 2.94 (q, 2H, J = 6.9 Hz, CH2NH, H-1); 3.50 (t, 2H,  
J = 6.8 Hz, CH2N=, H-4); 3.80 (s, 3H, OCH3); 6.77–6.82 (br s, 1H, NH); 6.98 (d, 2H, J = 8.8 Hz, H-2ʹ, 
H-6ʹ, Ar); 7.66 (d, 2H, J = 8.8 Hz, H-3ʹ, H-5ʹ, Ar); 8.24 (s, 1H, N=CH). 13C-NMR (DMSO-d6) δ: 27.4 
(C-2); 28.0 (C-3); 28.2 (OC(CH3)3); 39.6 (C-1); 55.2 (OCH3); 60.1 (C-4); 77.3 (OC(CH3)3); 114.0 (C-2ʹ, 
C-6ʹ, Ar); 129.0 (C-1ʹ, Ar); 129.3 (C-3ʹ, C-5ʹ, Ar); 155.5 (C=O); 159.7 (N=CH); 161.0 (C-4ʹ, Ar). 
{4-[(2-Chloro-benzylidene)-amino]-butyl}-carbamic acid tert-butyl ester (4c). Compound 4c was 
prepared in 98% yield (3.05 g) from 2-chlorobenzaldehyde 3c (1.41 g, 10 mmol) according to the 
standard procedure as yellowish viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.34–1.48 
(m, 2H, CH2, H-2); 1.56–1.63 (m, 2H, CH2, H-3); 2.96 (q, 2H, J = 6.7 Hz, CH2NH, H-1); 3.61 (t, 2H, 
J = 6.8 Hz, CH2N=, H-4); 6.78–6.82 (br s, 1H, NH); 7.36–7.52 (m, 3H, H-4ʹ, H-5ʹ, H-6ʹ, Ar);  
7.94–7.97 (m, 1H, H-3ʹ, Ar); 8.65 (s, 1H, N=CH). 13C-NMR (DMSO-d6) δ: 27.3 (C-2); 27.7 (C-3); 28.2 
(OC(CH3)3); 39.6 (C-1); 60.4 (C-4); 77.2 (OC(CH3)3); 127.4 (C-5ʹ, Ar); 128.0 (C-4ʹ, Ar); 129.8 (C-6ʹ, 
Ar); 132.0 (C-3ʹ, Ar); 132.7 (C-1ʹ, C-2ʹ, Ar); 133.8 (C-1ʹ, C-2ʹ, Ar); 155.5 (C=O); 156.6 (N=CH). 
{4-[(3-Methoxy-benzylidene)-amino]-butyl}-carbamic acid tert-butyl ester (4d). Compound 4d was 
prepared in 98% yield (3.03 g) from 3-methoxybenzaldehyde 3d (1.36 g, 10 mmol) according to the 
standard procedure as yellowish viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.36–1.45 
(m, 2H, CH2, H-2); 1.54–1.64 (m, 2H, CH2, H-3); 2.96 (q, 2H, J = 6.7 Hz, CH2NH, H-1); 3.54 (t, 2H, 
J = 6.7 Hz, CH2N=, H-4); 3.78 (s, 3H, OCH3), 6.76–6.82 (br s, 1H, NH); 6.99–7.03 (m, 1H, H-5ʹ, Ar); 
7.27–7.38 (m, 3H, H-2ʹ, H-4ʹ, H-6ʹ, Ar); 8.29 (s, 1H, N=CH). 13C-NMR (DMSO-d6) δ: 27.3 (C-2); 
27.8 (C-3); 28.2 (OC(CH3)3); 39.6 (C-1); 55.0 (OCH3); 60.1 (C-4); 77.2 (OC(CH3)3); 111.9 (C-5ʹ, Ar); 
116.6 (C-6ʹ, Ar); 120.6 (C-4ʹ, Ar); 129.6 (C-2ʹ, Ar); 137.6 (C-1ʹ, Ar); 155.5 (C=O); 159.4 (C-3ʹ, Ar); 
160.4 (C=N). 
{4-[(Benzo[1,3]dioxol-5-ylmethylene)-amino]-butyl}-carbamic acid tert-butyl ester (4e). Compound 
4e was prepared in 98% yield (3.13 g) from 3,4-methylenedioxybenzaldehyde 3e (1.51 g, 10 mmol) 
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according to the standard procedure as yellowish viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, 
Me3C); 1.30–1.46 (m, 2H, CH2, H-2); 1.51–1.61 (m, 2H, CH2, H-3); 2.94 (q, 2H, J = 6.9 Hz, CH2NH, 
H-1); 3.49 (t, 2H, J = 6.7 Hz, CH2N=, H-4); 6.07 (s, 2H, H-2ʹ, Ar), 6.77–6.82 (br s, 1H, NH); 6.97 (d, 
1H, J = 8 Hz, H-6ʹ, H-7ʹ, Ar); 7.16–7.20 (m, 1H, H-6ʹ, H-7ʹ, Ar); 7.27–7.28 (m, 1H, H-4ʹ, Ar), 8.20 (s, 
1H, N=CH). 13C-NMR (DMSO-d6) δ: 27.3 (C-2); 27.9 (C-3); 28.2 (OC(CH3)3); 39.6 (C-1); 59.8 (C-4); 
77.4 (OC(CH3)3); 101.4 (C-2ʹ, Ar); 105.8 (C-6ʹ, Ar); 108.1 (C-7ʹ, Ar); 124.0 (C-4ʹ, Ar); 130.9 (C-5ʹ, 
Ar); 147.8 (C-3aʹ, C-7aʹ, Ar); 149.3 (C-3aʹ, C-7aʹ, Ar); 155.5 (C=O); 160.0 (C=N). 
{4-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylene)-amino]-butyl}-carbamic acid tert-butylester (4f). 
Compound 4f was prepared in 99% yield (3.31 g) from 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
3f (1.50 g, 10 mmol) according to the standard procedure as yellowish viscous oil. 1H-NMR (DMSO-d6) δ: 
1.37 (s, 9H, Me3C); 1.34–1.45 (m, 2H, CH2, H-2); 1.51–1.60 (m, 2H, CH2, H-3); 2.94 (q, 2H, J = 6.8 Hz, 
CH2NH, H-1); 3.50 (t, 2H, J = 6.7 Hz, CH2N=, H-4); 4.23–4.30 (m, 4H, H-2ʹ, H-3ʹ, Ar), 6.77–6.81  
(br s, 1H, NH); 6.88–6.91 (m, 1H, H-7ʹ, Ar); 7.18–7.21 (m, 2H, H-5ʹ, H-8ʹ, Ar); 8.17 (s, 1H, N=CH).  
13C-NMR (DMSO-d6) δ: 27.3 (C-2); 27.9 (C-3); 28.2 (OC(CH3)3); 39.6 (C-1); 60.0 (C-4); 63.9 (C-2ʹ, 
Ar), 64.2 (C-3ʹ, Ar), 77.2 (OC(CH3)3); 116.0 (C-7ʹ, Ar); 117.1 (C-8ʹ, Ar); 121.2 (C-5ʹ, Ar); 129.8 (C-6ʹ, 
Ar); 143.4 (C-4aʹ, C-8aʹ, Ar); 145.4 (C-4aʹ, C-8aʹ, Ar); 155.5 (C=O); 159.6 (C=N). 
3.1.3. Standard Procedure for Reduction of Aldimines 4a–f into N-Boc Monoprotected Diamines 5a–f 
In a 50 mL two-necked round-bottomed flask, provided with a magnetic stirrer and reflux condenser, 
compound 4 (5 mmol) was dissolved in methanol p.a. (30 mL) under vigorous stirring and cooled at  
0 °C. To this solution was added by small portions commercial sodium borohydride NaBH4 (0.95 g,  
25 mmol) over a period of 20 min. The resulting suspension was stirred at 50 °C for 24 h (monitored 
by TLC on 0.2-mm precoated plates of silica gel 60 F-254, Merck). After cooling down to room 
temperature, the volatile compounds were removed in a rotary evaporator under reduced pressure, then 
deionized water (40 mL) was added in one portion to the crude residue. The mixture was transferred to a 
separating funnel and was extracted with dichloromethane (3 × 50 mL). The combined organic phases 
were dried over magnesium sulphate MgSO4, filtered on filter paper and the solvent was eliminated  
in vacuo. The crude residue was dried under high vacuum (10−2 Torr) at 25 °C for 2 h. The desired 
compound 5 was obtained as yellowish viscous oil and was further used without purification. 
(4-Phenylmethylamino-butyl)-carbamic acid tert-butyl ester (5a). Compound 5a was prepared in 93% 
yield (1.25 g) from [4-(benzylidene-amino)-butyl]-carbamic acid tert-butyl ester 4a (1.38 g, 5 mmol) 
according to the standard procedure that gave 5a as yellowish viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 
(s, 9H, Me3C); 1.34–1.42 (m, 4H, CH2, H-2, H-3); 2.45 (t, 2H, J = 6.2 Hz, CH2NH, H-4); 2.89–2.91 (m, 
2H, CH2NH, H-1); 3.66 (s, 2H, ArCH2NH); 6.78–6.82 (br s, 1H, NHCO); 7.18–7.13 (m, 1H, H-4ʹ, Ar); 
7.26–7.33 (m, 4H, H-2ʹ, H-3ʹ, H-5ʹ, H-6ʹ, Ar). 13C-NMR (DMSO-d6) δ: 27.4 (C-3); 26.8 (C-2); 39.8 
(C-1); 48.4 (C-4); 53.0 (ArCH2NH); 77.2 (OC(CH3)3); 126.3 (C-4ʹ, Ar); 127.8 (C-2ʹ, C-6ʹ, Ar); 128.0 
(C-3ʹ, C-5ʹ, Ar); 141,0 (C-1ʹ, Ar); 155,5 (C=O). 
[4-(4-Methoxy-phenylmethylamino)-butyl]-carbamic acid tert-butyl ester (5b). Compound 5b was 
prepared in 99% yield (1.52 g) from {4-[(4-methoxy-benzylidene)-amino]-butyl}-carbamic acid  
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tert-butyl ester 4b (1.53 g, 5 mmol) according to the standard procedure that gave 5b as yellowish 
viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.33–1.41 (m, 4H, H-2, H-3); 2.45 (t, 2H,  
J = 6.5 Hz, CH2NH, H-4); 2.88–2.90 (m, 2H, CH2NHCO, H-1); 3.60 (s, 2H, ArCH2NH); 3.72 (s, 3H, 
OCH3); 6.76–6.80 (br s, 1H, NHCO); 6.85 (d, 2H, J = 8.5 Hz, H-2ʹ, H-6ʹ, Ar); 7.22 (d, 2H, J = 8.6 Hz, 
H-3ʹ, H-5ʹ, Ar). 13C-NMR (DMSO-d6) δ: 26.6 (C-2); 27.4 (C-3); 28.2 (OC(CH3)3); 39.8 (C-4); 48.2  
(C-1); 52.3 (ArCH2NH); 54.9 (OCH3); 77.2 (OC(CH3)3); 113.4 (C-2ʹ, C-6ʹ, Ar); 129.0 (C-3ʹ, C-5ʹ, Ar); 
132.6 (C-1ʹ, Ar); 155.5 (C=O); 158.0 (C-4ʹ, Ar). 
[4-(2-Chloro-phenylmethylamino)-butyl]-carbamic acid tert-butyl ester (5c). Compound 5c was 
prepared in 85% yield (1.33 g) from {4-[(2-chloro-benzylidene)-amino]-butyl}-carbamic acid tert-butyl 
ester 4c (1.55 g, 5 mmol) according to the standard procedure that gave 5c as yellowish viscous oil. 
1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.34–1.43 (m, 4H, CH2, H-2, H-3, 4H); 2.47–2.52 (m, 2H, 
ArCH2NH, H-4); 2.88–2.92 (m, 2H, CH2NHCO, H-1); 3.75 (s, 2H, ArCH2NH); 6.77–6.80 (br s, 1H, 
NHCO); 7.21–7.33 (m, 2H, H-4ʹ, H-5ʹ, Ar); 7.37–7.4 (m, 1H, H-6ʹ, Ar); 7.5–7.53 (m, 1H, H-3ʹ, Ar). 
13C-NMR (DMSO-d6) δ: 26.7 (C-2); 27.4 (C-3); 28.2 (OC(CH3)3); 39.8 (C-4); 48.5 (C-1); 50.0 
(ArCH2NH); 77.2 (OC(CH3)3); 126.9 (C-5ʹ, Ar); 128.0 (C-4ʹ, Ar); 128.9 (C-6ʹ, Ar); 129.6 (C-3ʹ, Ar); 
132.5 (C-1ʹ, Ar); 138.2 (C-2ʹ, Ar); 155.5 (C=O). 
[4-(3-Methoxy-phenylmethylamino)-butyl]-carbamic acid tert-butyl ester (5d). Compound 5d was 
prepared in 90% yield (1.39 g) from {4-[(3-methoxy-benzylidene)-amino]-butyl}-carbamic acid  
tert-butyl ester 4d (1.53 g, 5 mmol) according to the standard procedure that gave 5d as pale pink 
viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.34–1.46 (m, 4H, H-2, H-3); 2.45 (t, 2H,  
J = 6.4 Hz, CH2NH, H-4); 2.89–2.91 (m, 2H, CH2NHCO, H-1); 3.64 (s, 2H, ArCH2NH); 3.74 (s, 3H, 
OCH3); 6.75–6.80 (br s, 1H, NHCO); 6.75–6.91 (m, 3H, H-4ʹ, H-5ʹ, H-6ʹ, Ar); 7.17–7.22 (m, 1H,  
H-2ʹ, Ar). 13C-NMR (DMSO-d6) δ: 26.8 (C-2); 27.4 (C-3); 28,2 (OC(CH3)3); 39.8 (C-4); 48.4 (C-1); 
52.9 (ArCH2NH); 54.8 (OCH3); 77.2 (OC(CH3)3); 111.8 (C-5ʹ, Ar); 113.2 (C-6ʹ, Ar); 120.0 (C-4ʹ, Ar); 
128.9 (C-2ʹ, Ar); 142.8 (C-1ʹ, Ar); 155.5 (C=O); 159.2 (C-3ʹ, Ar). 
{4-[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-butyl}-carbamic acid tert-butyl ester (5e). Compound 5e was 
prepared in 97% yield (1.56 g) from {4-[(benzo[1,3]dioxol-5-ylmethylene)-amino]-butyl}-carbamic acid 
tert-butyl ester 4e (1.60 g, 5 mmol) according to the standard procedure that gave 5e as yellowish 
viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.23–1.40 (m, 4H, H-2, H-3); 2.43 (t, 2H,  
J = 6.5 Hz, CH2NH, H-4); 2.89–2.91 (m, 2H, CH2NHCO, H-1); 3.64 (s, 2H, ArCH2NH); 5.96 (s, 2H,  
H-2ʹ, Ar); 6.73–6.82 (br s, 1H, NHCO); 6.73–6.90 (m, 3H, H-4ʹ, H-6ʹ, H-7ʹ, Ar). 13C-NMR (DMSO-d6) 
δ: 26.8 (C-2); 27.4 (C-3); 28.2 (OC(CH3)3); 39.8 (C-4); 48.1 (C-1); 52.7 (ArCH2NH); 77.2 (OC(CH3)3); 
100.6 (C-2ʹ, Ar); 107.7 (C-6ʹ, Ar); 108.2 (C-7ʹ, Ar); 120.8 (C-4ʹ, Ar); 135.0 (C-5ʹ, Ar); 145.7 (C-3aʹ,  
C-7aʹ, Ar); 147.1 (C-3aʹ, C-7aʹ, Ar); 155.5 (C=O). 
{4-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-butyl}-carbamic acid tert-butyl ester (5f). 
Compound 5f was prepared in 88% yield (1.48 g) from {4-[(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)-
amino]-butyl}-carbamic acid tert-butylester 4f (1.67 g, 5 mmol) according to the standard procedure 
that gave 5f as yellowish viscous oil. 1H-NMR (DMSO-d6) δ: 1.37 (s, 9H, Me3C); 1.33–1.43 (m, 4H,  
H-2, H-3); 2.42 (t, 2H, J = 6.4 Hz, CH2NH, H-4); 2.88–2.90 (m, 2H, CH2NHCO, H-1); 3.53 (s, 2H, 
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ArCH2NH); 4.20 (s, 4H, H-2ʹ, H-3ʹ, Ar); 6.75–6.80 (br s, 1H, NHCO); 6.75–6.80 (m, 3H, H-5ʹ, H-7ʹ,  
H-8ʹ, Ar). 13C-NMR (DMSO-d6) δ: 26.8 (C-2); 27.4 (C-3); 28.2 (OC(CH3)3); 39.8 (C-4); 48.2 (C-1); 52.3 
(ArCH2NH); 63.9 (C-2ʹ, C-3ʹ, Ar); 64.0 (C-2ʹ, C-3ʹ, Ar); 77.2 (OC(CH3)3); 116.4 (C-7ʹ, Ar); 116.5 (C-8ʹ, 
Ar); 120.6 (C-5ʹ, Ar); 134.0 (C-6ʹ, Ar); 141.9 (C-4aʹ, C-8aʹ, Ar); 143.0 (C-4aʹ, C-8aʹ, Ar); 155.5 (C=O). 
3.1.4. Standard Procedure for the Preparation of Hydrochloride Salts 6a–f after Deprotection of N-Boc 
Monoprotected Diamines 5a–f 
In a 100 mL two-necked round-bottomed flask provided with a magnetic stirrer and condenser,  
N-Boc monoprotected diamine 5 (12.1 mmol, 1 equiv.) was solubilized in 1,4-dioxane (80 mL) at room 
temperature under vigorous stirring for 10 min. To this homogeneous solution was added dropwise for 
1 h a solution of 6 M HCl (20 mL). The reaction mixture was stirred during 4 h at 25 °C and was 
concentrated in a rotary evaporator under reduced pressure for elimination of volatile compounds.  
To the crystallized crude reaction mixture was added 60 mL of anhydrous Et2O and after triturating, 
the insoluble salt 6 was collected by filtration, on a Büchner funnel (porosity N°4) then washed with  
6 × 10 mL of Et2O. The desired salt 6 was dried under high vacuum (10−2 Torr) at 25 °C for 1 h that 
gave a yellowish or white powder and was further used without purification. 
N-1-Phenylmethyl-butane-1,4-diamine hydrochloride (6a). Compound 6a was prepared in 84%  
yield (2.18 g) from (4-phenylmethylamino-butyl)-carbamic acid tert-butyl ester 5a (3.37 g, 12.1 mmol) 
according to the standard procedure as yellowish powder. Mp > 260 °C. 1H-NMR (DMSO-d6) δ:  
1.57–1.67 (m, 2H, CH2, H-3); 1.70–1.81 (m, 2H, CH2, H-2); 2.79 (t, 2H, J = 7.3 Hz, CH2NH, H-4); 
2.89 (t, 2H, J = 7.5 Hz, CH2NH2, H-1); 4.10 (s, 2H, CH2NH, H-4); 7.4–7.45 (m, 3H, H-3ʹ, H-4ʹ, H-5ʹ, 
Ar); 7.58–7.62 (m, 2H, H-2ʹ, H-6ʹ, Ar); 8.19 (br s, 2H, NH2); 9.57 (br s, 1H, NH). 13C-NMR (DMSO-d6) 
δ: 22.3 (C-3); 24.0 (C-2); 38.0 (C-4); 45.5 (C-1); 49.7 (ArCH2NH); 128.5 (C-3ʹ, C-5ʹ, Ar); 128.8 (C-4ʹ, 
Ar); 130.1 (C-2ʹ, C-6ʹ, Ar); 132.0 (C-1ʹ, Ar). 
N-1-(4-Methoxy-phenylmethyl)-butane1,4-diamine hydrochloride (6b). Compound 6b was prepared in 
97% yield (2.87 g) from (4-methoxyphenylmethylamino-butyl)-carbamic acid tert-butyl ester 5b (3.73 g, 
12.1 mmol) according to the standard procedure as pale brownish powder. Mp > 260 °C. 1H-NMR 
(DMSO-d6) δ: 1.57–1.66 (m, 2H, H-3); 1.69–1.79 (m, 2H, H-2); 2.77–2.84 (m, 4H, H-1, H-4); 3.76 (s, 
3H, OCH3); 4.03 (s, 2H, ArCH2NH); 6.97 (d, 2H, J = 8.7 Hz, H-2ʹ, H-6ʹ, Ar); 7.51 (d, 2H, J = 8.7 Hz, 
H-3ʹ, H-5ʹ, Ar), 8.15 (br s, 2H, NH2); 9.41 (br s, 1H, NH). 13C-NMR (DMSO-d6) δ: 22.3 (C-3); 24.0 
(C-2); 38.0 (C-4); 45.3 (C-1); 49.2 (ArCH2NH); 55.2 (OCH3); 113.9 (C-2ʹ, C-6ʹ, Ar); 123.7 (C-1ʹ, Ar); 
131.6 (C-3ʹ, C-5ʹ, Ar); 159.6 (C-4ʹ, Ar). 
N-1-(2-Chloro-phenylmethyl)-butane1,4-diamine hydrochloride (6c). Compound 6c was prepared in 
98% yield (2.95 g) from (2-chlorophenylmethylamino-butyl)-carbamic acid tert-butyl ester 5c (3.79 g, 
12.1 mmol) according to the standard procedure as pale brownish powder. Mp = 206–208 °C.  
1H-NMR (DMSO-d6) δ: 1.60–1.69 (m, 2H, H-3); 1.74–1.84 (m, 2H, H-2); 2.73–2.84 (m, 2H, CH2NH, 
H-4); 2.93–3.02 (m, 2H, CH2NH2, H-1); 4.23 (t, 2H, J = 5.9 Hz, ArCH2NH); 7.39–7.48 (m, 2H, H-4ʹ, 
H-5ʹ, Ar); 7.52–7.56 (m, 1H, H-6ʹ, Ar); 7.81–7.85 (m, 1H, H-3ʹ, Ar); 8.18 (br s, 2H, NH2, 2H); 9.68  
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(br s, 1H, NH). 13C-NMR (DMSO-d6) δ: 22.3 (C-3); 24.0 (C-2); 38.0 (C-4); 46.1 (C-1); 46.7 (ArCH2NH); 
127.5 (C-5ʹ, Ar); 129.5 (C-4ʹ, Ar); 129.9 (C-1ʹ, Ar); 130.7 (C-6ʹ, Ar); 131.9 (C-3ʹ, Ar); 133.5 (C-2ʹ, Ar). 
N-1-(3-Methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride (6d). Compound 6d was prepared in 
98% yield (2.98 g) from [4-(3-methoxy-phenylmethylamino)-butyl]-carbamic acid tert-butyl ester 5d 
(3.73 g, 12.1 mmol) according to the standard procedure as pale brownish powder. Mp = 190–192 °C. 
1H-NMR (DMSO-d6) δ: 1.58–1.67 (m, 2H, H-3); 1.71–1.81 (m, 2H, H-2); 2.78 (t, 2H, J = 7.3 Hz, 
CH2NH, H-4); 2.87 (t, 2H, J = 7.6 Hz, CH2NH2, H-1); 3.77 (s, 3H, OCH3); 4.08 (t, 2H, J = 5.6 Hz, 
ArCH2NH); 6.94–6.97 (m, 1H, H-5ʹ, Ar); 7.12–7.14 (m, 1H, H-6ʹ, Ar); 7.29–7.35 (m, 2H, H-2ʹ, H-4ʹ, 
Ar); 8.18 (br s, 2H, NH2); 9.58 (br s, 1H, NH). 13C-NMR (DMSO-d6) δ: 22.3 (C-3); 24.0 (C-2); 38.0  
(C-4); 45.5 (C-1); 49.7 (ArCH2NH); 55.2 (OCH3); 114.5 (C-5ʹ, Ar); 115.5 (C-6ʹ, Ar); 122.0 (C-4ʹ, Ar); 
129.6 (C-2ʹ, Ar); 133.4 (C-1ʹ, Ar); 159.2 (C-3ʹ, Ar). 
N-1-Benzo[1,3]dioxol-5-ylmethyl-butane-1,4-diamine hydrochloride (6e). Compound 6e was prepared 
in 72% yield (2.25 g) from {4-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-butyl}-carbamic acid tert-butyl 
ester 5e (3.90 g, 12.1 mmol) according to the standard procedure as pale brownish powder. Mp > 260 °C. 
1H-NMR (DMSO-d6) δ: 1.58–1.67 (m, 2H, H-3); 1.71–1.81 (m, 2H, H-2); 2.78 (t, 2H, J = 7.3 Hz, 
CH2NH, H-4); 2.87 (t, 2H, J = 7.6 Hz, CH2NH2, H-1); 3.77 (s, 3H, OCH3); 4.08 (t, 2H, J = 5.6 Hz, 
ArCH2NH); 6.94–6.97 (m, 1H, H-5ʹ, Ar); 7.12–7.14 (m, 1H, H-6ʹ, Ar); 7.29–7.35 (m, 2H, H-2ʹ, H-4ʹ, 
Ar); 8.18 (br s, 2H, NH2); 9.58 (br s, 1H, NH). 13C-NMR (DMSO-d6) δ: 22.3 (C-3); 24.0 (C-2); 38.0 
(C-4); 45.2 (C-1); 49.4 (ArCH2NH); 101.2 (C-2ʹ, Ar); 108.2 (C-6ʹ, Ar); 110.4 (C-7ʹ, Ar); 124.1 (C-4ʹ, 
Ar); 125.4 (C-5ʹ, Ar); 147.2 (C-3aʹ, C-7aʹ, Ar); 147.6 (C-3aʹ, C-7aʹ, Ar). 
N-1-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-butane-1,4-diamine hydrochloride (6f). Compound 6e 
was prepared in 92% yield (3.04 g) from {4-[(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-
butyl}-carbamic acid tert-butyl ester 5f (4.07 g, 12.1 mmol) according to the standard procedure as 
pale brownish powder. Mp = 239–241 °C. 1H-NMR (DMSO-d6) δ: 1.57–1.66 (m, 2H, H-3); 1.68–1.78 
(m, 2H, H-2); 2.73–2.82 (m, 4H, H-1, H-4); 3.97 (t, 2H, J = 5.4 Hz, ArCH2NH); 4.24 (s, 4H, 
OCH2CH2O); 6.87 (d, 1H, J = 8.2 Hz, H-7ʹ, Ar); 7.01–7.04 (m, 1H, H-8ʹ, Ar); 7.15 (m, 1H, H-5ʹ, Ar); 
8.18 (br s, 2H, NH2); 9.43 (br s, 1H, NH). 13C-NMR (DMSO-d6) δ: 22.3 (C-3); 24.0 (C-2); 38.0 (C-4); 
45.2 (C-1); 49.1 (ArCH2NH); 64.0 (C-2ʹ, Ar); 64.1 (C-3ʹ, Ar); 117.0 (C-7ʹ, Ar); 119.0 (C-8ʹ, Ar); 123.2 
(C-5ʹ, Ar); 124.7 (C-6ʹ, Ar); 143.1 (C-4aʹ, C-8aʹ, Ar); 143.8 (C-4aʹ, C-8aʹ, Ar). 
3.1.5. Standard Procedure for the Preparation of N-Substituted 5-Arylidene Rhodanine Derivatives  
9a–f under Microwave Irradiation Using “One-Pot Two-steps” Protocol 
In a 10 mL glass tube were placed successively bis-(carboxymethyl)trithiocarbonate 7 (0.11 g,  
0.50 mol, 1 equiv.), dimethoxyethane (2 mL), triethylamine (135 mL, 101 mg, 1 mmol, 2 equiv. or  
202 mL, 152 mg, 1.5 mmol, 3 equiv.) and hydrochloride salt 6 (0.5 mmol, 1 equiv.). The glass tube was 
sealed with a snap cap and placed in the Monowave® 300 Anton Paar microwave cavity (p = 800 Watt). 
The reaction mixture was irradiated at 90 °C for 15–60 min. under vigorous magnetic stirring. After 
microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature, 
aldehyde 3 (0.5 mol, 1 equiv.) was added to the cooled reaction mixture which was immediately 
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submitted to microwave irradiation at 110 °C for 5–30 min. After cooling down to room temperature, 
the volatile compounds of the reaction mixture were removed in a rotary evaporator under reduced 
pressure. To the crude reaction mixture was added 4 mL of MeOH and after triturating, the insoluble 
product 9 was collected by filtration on a Büchner funnel (porosity N°4), washed with deionized water  
(5 mL), triturated and mixing with ethanol (3 × 5 mL) during 3 h, washed successively with ethanol  
(5 mL) and anhydrous ether (5 × 2 mL), then dried under high vacuum (10−2 Torr) at 25 °C for 1 h. The 
desired compound 9 was eventually purified by recrystallization in EtOH after control by 1H-NMR in 
solution of CDCl3/TFA (98:2). 
(5Z)3-[4-(4-Methoxyphenylmethylamino)butyl]-5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3-
thiazolidin-4-one (9a). According to the standard procedure, compound 9a was prepared in 10% yield 
(23 mg) from N-1-(4-methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride 6b (122.3 mg,  
0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and piperonaldehyde 3e  
(75.1 mg, 0.5 mmol, 1 equiv.) after 30 min. at 90 °C, followed by a second reaction time of 30 min. at 
110 °C (for condensation step with 3e), which gave 9a as a yellowish powder. Mp = 170–229 °C 
(decomposition). 1H-NMR (CDCl3/TFA 98:2) δ: 1.61–1.69 (m, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.05–3.11 (m, 
2H, ArCH2NH); 3.73 (s, 3H, OCH3); 4.00–4.08 (m, 4H, CH2, H-1ʹʹ, H-4ʹʹ), 5.97 (s, 2H, CH2, H-2ʹ); 
6.80–7.16 (m, 7H, H-2ʹʹʹ, H-3ʹʹʹ, H-5ʹʹʹ, H-6ʹʹʹ, H-4ʹ, H-6ʹ, H-7ʹ, Ar); 7.55 (br s, 1H, NH); 7.61 (s, 1H, 
HC=C). 13C-NMR (CDCl3/TFA 98:2) δ: 23.1 (C-2ʹʹ, 3ʹʹ); 23.8 (C-3ʹʹ, 2ʹʹ); 44.2 (C-4ʹʹ, C-1ʹʹ); 47.0 
(ArCH2NH); 52.1 (C-1ʹʹ, C-4ʹʹ); 55.5 (OCH3); 102.2 (C-2ʹ); 109.4 (C-2ʹʹʹ, C-6ʹʹʹ); 109.5 (C-3ʹʹʹ, C-5ʹʹʹ); 
115.0 (C-6ʹ); 120.0 (C-1ʹʹʹ); 127.5 (C=CH); 128.2 (C-7ʹ); 131.2 (C-4ʹ); 135.0 (C=CH); 148.8 (C-5ʹ); 
148.9 (C-4ʹʹʹ); 150.6 (C-3ʹa); 150.9 (C-7ʹa); 169.4 (C=O, C-4); 192.9 (C=S, C-2). HRMS, m/z: 
457.1256 found (calculated for C23H25N2O4S2 [M + H]+ requires 457.1253). 
(5Z)3-[4-(4-Methoxyphenylmethylamino)butyl]-5-(4-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-
one (9b). According to the standard procedure, compound 9b was prepared in 6% yield (13.3 mg) from 
N-1-(4-methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride 6b (122.3 mg, 0.5 mmol, 1 equiv.), 
triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and 4-methoxybenzaldehyde 3b (68.1 mg, 0.5 mmol, 
1 equiv.) after 30 min. at 90 °C, followed by a second reaction time of 30 min. at 110 °C (for 
condensation step with 3b), which gave 9b as a yellowish powder. Mp = 253–255 °C. 1H-NMR 
(CDCl3/TFA 98:2) δ: 1.67–1.73 (m, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.07–3.13 (m, 2H, ArCH2NH); 3.81 (s, 6H, 
ArOCH3); 4.04–4.11 (s, 4H, CH2, H-1ʹʹ, H-4ʹʹ), 6.94 (dd, 4H, J = 8.8 Hz, H-2ʹ, H-6ʹ, H-2ʹʹʹ, H-6ʹʹʹ, Ar); 
7.40 (d, 4H, J = 8.8 Hz, H-3ʹ, H-5ʹ, H-3ʹʹʹ, H-5ʹʹʹ, Ar); 7.60 (br s, 1H, NH); 7.67 (s, 1H, CH=).  
13C-NMR (CDCl3/TFA 98:2) δ: 24.3 (C-2ʹʹ, C-3ʹʹ); 44.0 (C-1ʹʹ, C-4ʹʹ); 46.8 (ArCH2NH); 55.6 (C-4ʹ, 
OCH3, C-4ʹʹʹ, OCH3); 115.1 (C-2ʹ, C-6ʹ, C-2ʹʹʹ, C-6ʹʹʹ); 119.6 (C-1ʹ, C-1ʹʹʹ); 126.0 (C=); 133.1 (C-3ʹ,  
C-5ʹ, C-3ʹʹʹ, C-5ʹʹʹ); 130.5 (C-5ʹ, C-5ʹʹʹ); 134.6 (CH=); 162.0 (C-4ʹ, C-4ʹʹʹ); 169.0 (C=O, C-4); 193.2 
(C=S, C-2). HRMS, m/z: 443.1463 found (calculated for C23H27N2O3S2 [M + H]+ requires 443.1460). 
(5Z)3-[4-(4-Methoxyphenylmethylamino)butyl]-5-(2,3-dihydro-1,4-benzodioxin-6-ylmethylene)-2-
thioxo-1,3-thiazolidin-4-one (9c). According to the standard procedure, compound 9c was prepared in 
5% yield (11.8 mg) from N-1-(4-methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride 6b (122.3 mg, 
0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and 2,3-dihydro-1,4-benzodioxin-
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6-carboxaldehyde 3f (82.1 mg, 0.5 mmol, 1 equiv.) after 30 min. at 90 °C, followed by a second reaction 
time of 30 min. at 110 °C (for condensation step with 3f), which gave 9c as a yellowish powder.  
Mp = 255–261 °C. 1H-NMR (CDCl3/TFA 98:2) δ: 1.68 (s, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.03–3.08 (m, 2H, 
ArCH2NH); 3.73 (s, 3H, OCH3); 4.07 (s, 4H, CH2, H-1ʹʹ, H-4ʹʹ), 4.20–4.25 (m, 2H, CH2, H-2ʹ, H-3ʹ); 
6.84–6.97 (m, 7H, H-5ʹ, H-7ʹ, H-8ʹ, H-2ʹʹʹ, H-3ʹʹʹ, H-5ʹʹʹ, H-6ʹʹʹ, Ar); 7.58 (s, 1H, CH=); 7.60 (br s, 1H, 
NH). 13C-NMR (CDCl3/TFA 98:2) δ: 24.2 (C-2ʹʹ, C-3ʹʹ); 44.1 (C-4ʹʹ, C-1ʹʹ); 47.1 (ArCH2NH); 55.0 
(OCH3); 64.2 (C-2ʹ); 64.8 (C-3ʹ); 118.4 (C-5ʹ, C-7ʹ, C-8ʹ); 119.7 (C-2ʹʹʹ, C-6ʹʹʹ); 120.3 (C=); 125.7  
(C-3ʹʹʹ, C-5ʹʹʹ); 126.8 (C-6ʹ); 135.0 (CH=); 143.9 (C-8ʹa); 146.7 (C-4ʹa); 169.5 (C=O, C-4); 193.2 (C=S, 
C-2). HRMS, m/z: 471.1412 found (calculated for C24H27N2O4S2 [M + H]+ requires 471.1415). 
(5Z)3-[4-(4-Methoxyphenylmethylamino)butyl]-5-(4-hydroxy-3-methoxybenzylidene)-2-thioxo-1,3-
thiazolidin-4-one (9d). According to the standard procedure, compound 9d was prepared in 30% yield 
(68.8 mg) from N-1-(4-methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride 6b (122.3 mg,  
0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and 4-hydroxy-3-
methoxybenzaldehyde 3g (76.1 mg, 0.5 mmol, 1 equiv.) after 30 min. at 90 °C, followed by a second 
reaction time of 30 min. at 110 °C (for condensation step with 3g), which gave 9d as a yellowish 
powder. Mp = 191–193 °C. 1H-NMR (CDCl3/TFA 98:2) δ: 1.69 (m, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.06–3.07 
(m, 2H, ArCH2NH); 3.72 (s, 3H, C-4ʹʹʹ, OCH3); 3.86 (s, 3H, C-3ʹ, OCH3); 4.04–4.08 (m, 4H, CH2,  
H-1ʹʹ, H-4ʹʹ), 6.81–7.17 (m, 7H, H-2ʹ, H-5ʹ, H-6ʹ, H-2ʹʹʹ, H-3ʹʹʹ, H-5ʹʹʹ, H-6ʹʹʹ, Ar); 7.55 (br s, 1H, NH); 
7.60 (s, 1H, CH=C). 13C-NMR (CDCl3/TFA 98:2) δ: 23.1 (C-2ʹʹ, C-3ʹʹ); 23.9 (C-2ʹʹ, C-3ʹʹ); 43.1 (C-1ʹʹ, 
C-4ʹʹ); 47.0 (ArCH2NH); 55.5 (ArOCH3); 56.1 (ArOCH3); 112.6 (C-6ʹ); 115.0 (C-2ʹʹʹ, C-6ʹʹʹ); 115.6  
(C-2ʹ); 118.9 (C-1ʹʹʹ); 121.2 (C=); 125.9 (C-1ʹ); 126.8 (C-5ʹ); 131.2 (C-3ʹʹʹ, C-5ʹʹʹ); 135.9 (CH=); 147.2 
(C-4ʹʹʹ); 148.9 (C-3ʹ); 160.8 (C-4ʹ); 169.4 (C=O, C-4); 193.1 (C=S, C-2). HRMS, m/z: 459.1412 found 
(calculated for C23H27N2O4S2 [M + H]+ requires 459.1416). 
(5Z)3-[4-(3-Methoxyphenylmethylamino)butyl]-5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3-
thiazolidin-4-one (9e). According to the standard procedure, compound 9e was prepared in 21% yield 
(48.0 mg) from N-1-(3-methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride 6d (122.3 mg,  
0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and piperonaldehyde 3e (75.1 mg, 
0.5 mmol, 1 equiv.) after 15 min. at 90 °C, followed by a second reaction time of 15 min. at 110 °C (for 
condensation step with 3e), which gave 9e as a yellowish powder. Mp = 178–246 °C (decomposition). 
1H-NMR (CDCl3/TFA 98:2) δ: 1.82 (s, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.19–3.22 (m, 2H, ArCH2NH); 3.83 (s, 
3H, OCH3); 4.13-4.23 (m, 4H, CH2, H-1ʹʹ, H-4ʹʹ), 6.10 (s, 2H, CH2, H-2ʹ); 6.92–7.28 (m, 6H, H-2ʹʹʹ,  
H-4ʹʹʹ, H-6ʹʹʹ, H-4ʹ, H-6ʹ, H-7ʹ, Ar), 7.33–7.38 (m, 1H, H-5ʹʹʹ, Ar), 7.55 (br s, 1H, NH); 7.70 (s, 1H, 
CH=). 13C-NMR (CDCl3/TFA 98:2) δ: 23.1 (C-2ʹʹ, C-3ʹʹ); 23.9 (C-3ʹʹ, C-2ʹʹ); 42.9 (C-4ʹʹ, C-1ʹʹ); 46.8 
(ArCH2NH); 52.1 (C-1ʹʹ, C-4ʹʹ); 55.3 (OCH3); 102.1 (C-2ʹ); 109.3 (C-6ʹʹʹ); 109.4 (C-5ʹʹʹ); 114.9 (C-4ʹʹʹ); 
115.9 (C-2ʹʹʹ); 119.8 (C-1ʹʹʹ); 121.8 (C-6ʹ); 127.4 (C=); 127.6 (C-5ʹ); 127.9 (C-7ʹ); 130.7 (C-4ʹ); 134.5 
(CH=); 148.8 (C-7ʹa); 150.5 (C-3ʹa); 160.3 (C-3ʹʹʹ); 168.5 (C=O, C-4); 193.1 (C=S, C-2). HRMS, m/z: 
457.1259 found (calculated for C23H25N2O4S2 [M + H]+ requires 457.1257). 
(5Z)3-[4-(3-Methoxyphenylmethylamino)butyl]-5-(2,3-dihydro-1,4-benzodioxin-6-ylmethylene)-2-
thioxo-1,3-thiazolidin-4-one (9f). According to the standard procedure, compound 9c was prepared in 9% 
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yield (21.2 mg) from N-1-(3-methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride 6d (122.3 mg,  
0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and 2,3-dihydro-1,4-
benzodioxin-6-carboxaldehyde 3f (82.1 mg, 0.5 mmol, 1 equiv.) after 15 min. at 90 °C, followed by a 
second reaction time of 15 min. at 110 °C (for condensation step with 3f), which gave 9f as  
a yellowish powder. Mp = 247–251 °C. 1H-NMR (CDCl3/TFA 98:2) δ: 1.84 (s, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 
3.04–3.12 (m, 2H, ArCH2NH); 3.95 (s, 3H, OCH3); 4.23 (s, 4H, CH2, H-1ʹʹ, H-4ʹʹ); 4.37–4.40 (m, 4H, 
H-2ʹ, H-3ʹ); 6.99–7.28 (m, 6H, H-2ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ, H-6ʹʹʹ, H-5ʹ, H-7ʹ, H-8ʹ, Ar); 7.60 (br s, 1H, NH); 
7.74 (s, 1H, CH=). 13C-NMR (CDCl3/TFA 98:2) δ: 24.1 (C-2ʹʹ, C-3ʹʹ); 44.1 (C-1ʹʹ, C-4ʹʹ); 47.3 
(ArCH2NH); 64.2 (C-2ʹ); 64.8 (C-3ʹ); 118.5 (C-5ʹ, C-7ʹ, C-8ʹ); 119.8 (C-4ʹʹʹ, C-6ʹʹʹ); 125.9 (C-2ʹʹʹ,  
C-5ʹʹʹ); 126.8 (C=); 135.3 (CH=); 143.8 (C-8ʹa); 146.6 (C-4ʹa); 168.5 (C=O, C-4); 193.3 (C=S, C-2). 
HRMS, m/z: 471.1412 found (calculated for C24H27N2O4S2 [M + H]+ requires 471.1415). 
(5Z)3-[4-(3-Methoxyphenylmethylamino)butyl]-5-(3-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-
one (9g). According to the standard procedure, compound 9g was prepared in 5% yield (11.1 mg) from 
N-1-(3-methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride 6d (122.3 mg, 0.5 mmol, 1 equiv.), 
triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and 3-methoxybenzaldehyde 3d (68.1 mg, 0.5 mmol,  
1 equiv.) after 30 min. at 90 °C, followed by a second reaction time of 30 min at 110 °C (for condensation 
step with 3d), which gave 9g as a yellowish powder. Mp = 225–227 °C. 1H-NMR (CDCl3/TFA 98:2) 
δ: 1.73 (s, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.06–3.10 (m, 2H, ArCH2NH); 3.80 (s, 6H, ArOCH3); 4.11 (s, 4H, CH2, 
H-1ʹʹ, H-4ʹʹ), 6.93–6.96 (m, 4H, H-2ʹ, H-6ʹ, H-2ʹʹʹ, H-6ʹʹʹ, Ar); 7.04 (d, 2H, J = 7.7 Hz, H-4ʹ, H-4ʹʹʹ, Ar), 
7.32 (m, 2H, H-5ʹ, H-5ʹʹʹ, Ar), 7.55 (br s, 1H, NH); 7.66 (s, 1H, CH=). 13C-NMR (CDCl3/TFA 98:2) δ: 
24.3 (C-2ʹʹ, C-3ʹʹ); 44.0 (C-1ʹʹ, C-4ʹʹ); 47.1 (ArCH2NH); 55.5 (ArOCH3); 115.3 (C-6ʹ, C-6ʹʹʹ); 117.3  
(C-2ʹ, C-2ʹʹʹ); 123.1 (C=); 123.6 (C-4ʹ, C-4ʹʹʹ); 130.5 (C-5ʹ, C-5ʹʹʹ); 134.0 (CH=); 134.5 (C-1ʹ, C-1ʹʹʹ); 
160.0 (C-3ʹ, C-3ʹʹʹ); 168.5 (C=O, C-4); 193.3 (C=S, C-2). HRMS, m/z: 443.1463 found (calculated for 
C23H27N2O3S2 [M + H]+ requires 443.1465). 
(5Z)3-[4-(1,3-Benzodioxol-5-ylmethylamino)butyl]-5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3-
thiazolidin-4-one (9h). According to the standard procedure, compound 9h was prepared in 59% yield 
(139 mg) from N-1-benzo[1,3]dioxol-5-ylmethyl-butane-1,4-diamine hydrochloride 6e (129.4 mg,  
0.5 mmol, 1 equiv.), triethylamine (135 μL, 101 mg., 1 mmol, 2 equiv.) and piperonaldehyde 3e (75.1 mg, 
0.5 mmol, 1 equiv.) after 15 min. at 90 °C, followed by a second reaction time of 15 min. at 110 °C 
(for condensation step with 3e), which gave 9h as a yellowish powder. Mp = 245–256 °C. 1H-NMR 
(CDCl3/TFA 98:2) δ: 1.74 (s, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.04–3.05 (m, 2H, ArCH2NH); 4.05–4.07 (m, 4H, 
CH2, H-1ʹʹ, H-4ʹʹ); 5.91 (s, 2H, CH2, H-2ʹʹʹ); 6.00 (s, 2H, CH2, H-2ʹ); 6.72–7.01 (m, 6H, H-4ʹ, H-6ʹ,  
H-7ʹ, H-4ʹʹʹ, H-6ʹʹʹ, H-7ʹʹʹ, Ar); 7.58 (s, 1H, CH=); 7.65 (br s, 1H, NH);. 13C-NMR (CDCl3/TFA 98:2) 
δ: 23.1 (C-2ʹʹ, C-3ʹʹ); 24.0 (C-3ʹʹ); 43.1 (C-1ʹʹ, C-4ʹʹ); 46.5 (ArCH2NH); 51.9 (C-4ʹʹ, C-1ʹʹ); 101.8 (C-2ʹ,  
C-2ʹʹʹ); 102.2 (C-2ʹʹʹ, C-2ʹ); 109.0 (C-6ʹʹʹ); 109.3 (C-6ʹ); 109.4 (C-7ʹʹʹ); 109.8 (C-7ʹ); 119.8 (C-5ʹʹʹ); 
122.6 (C=); 124.3 (C-4ʹʹʹ); 127.4 (C-4ʹ); 128.1 (C-5ʹ); 134.9 (CH=); 148.6 (C-7ʹa); 148.9 (C-3ʹa); 149.2  
(C-7ʹʹʹa); 150.6 (C-3ʹʹʹa); 168.9 (C=O, C-4); 193.0 (C=S, C-2). HRMS, m/z: 471.1048 found 
(calculated for C23H23N2O5S2 [M + H]+ requires 471.1049). 
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(5Z)3-[4-(1,3-Benzodioxol-5-ylmethylamino)butyl]-5-(2,3-dihydro-1,4-benzodioxin-6-ylmethylene)-2-
thioxo-1,3-thiazolidin-4-one (9i). According to the standard procedure, compound 9i was prepared in 
59% yield (143 mg) from N-1-benzo[1,3]dioxol-5-ylmethyl-butane-1,4-diamine hydrochloride 6e 
(129.4 mg, 0.5 mmol, 1 equiv.), triethylamine (135 μL, 101 mg., 1 mmol, 2 equiv.) and 2,3-dihydro-
1,4-benzodioxin-6-carboxaldehyde 3f (82.1 mg, 0.5 mmol, 1 equiv.) after 15 min. at 90 °C, followed 
by a second reaction time of 15 min. at 110 °C (for condensation step with 3f), which gave 9i as  
a yellowish powder. Mp = 253–257 °C. 1H-NMR (CDCl3/TFA 98:2) δ: 1.68 (s, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 
3.05–3.06 (m, 2H, ArCH2NH); 4.03–4.04 (m, 4H, CH2, H-1ʹʹ, H-4ʹʹ); 4.20–4.25 (m, 4H, CH2, H-2ʹ,  
H-3ʹ); 5.89 (s, 2H, CH2, H-2ʹʹʹ); 6.70 (s, 3H, H-4ʹʹʹ, H-6ʹʹʹ, H-7ʹʹʹ, Ar); 6.85–6.96 (m, 3H, H-5ʹ, H-7ʹ,  
H-8ʹ, Ar); 7.50 (br s, 1H, NH); 7.55 (s, 1H, CH=). 13C-NMR (CDCl3/TFA 98:2) δ: 23.1 (C-2ʹʹ, C-3ʹʹ); 
23.8 (C-3ʹʹ, C-2ʹʹ); 43.1 (C-1ʹʹ, C-4ʹʹ); 47.0 (ArCH2NH); 52.4 (C4ʹʹ, C-1ʹʹ); 64.2 (C-2ʹ, C-3ʹ); 64.8 (C-3ʹ, 
C-2ʹ); 101.8 (C-2ʹʹʹ); 109.1 (C-6ʹʹʹ); 109.5 (C-7ʹʹʹ); 118.5 (C-7ʹ); 119.7 (C-5ʹʹʹ); 119.8 (C-8ʹ); 122.3 
(C=); 124.1 (C-4ʹʹʹ); 125.9 (C-5ʹ); 126.6 (C-6ʹ); 135.5 (CH=); 144.0 (C-7ʹʹʹa); 146.9 (C-3ʹʹʹa); 148.6  
(C-8ʹa); 149.4 (C-4ʹa); 169.5 (C=O, C-4); 193.2 (C=S, C-2). HRMS, m/z: 485.1205 found (calculated 
for C24H25N2O5S2 [M + H]+ requires 485.1203). 
(5Z)3-[4-(1,3-Benzodioxol-5-ylmethylamino)butyl]-5-(4-hydroxy-benzylidene)-2-thioxo-1,3-thiazolidin-4-
one (9j). According to the standard procedure, compound 9j was prepared in 34% yield (75.2 mg) from 
N-1-benzo[1,3]dioxol-5-ylmethyl-butane-1,4-diamine hydrochloride 6e (129.4 mg, 0.5 mmol, 1 equiv.), 
triethylamine (135 μL, 101 mg, 1 mmol, 2 equiv.) and 4-hydroxybenzaldehyde 3h (61.1 mg, 0.5 mmol, 
1 equiv.) after 15 min. at 90 °C, followed by a second reaction time of 15 min. at 110 °C (for condensation 
step with 3h), which gave 9i as a orange powder. Mp = 93–124 °C (decomposition). 1H-NMR 
(CDCl3/TFA 98:2) δ: 1.59–1.73 (m, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.01–3.13 (m, 2H, ArCH2NH); 4.00–4.05 
(m, 4H, CH2, H-1ʹʹ, H-4ʹʹ); 5.88 (s, 2H, CH2, H-2ʹʹʹ); 6.66–6.69 (m, H-4ʹʹʹ, H-6ʹʹʹ, H-7ʹʹʹ, Ar); 6.86 (dd, 
2H, J = 8.7 Hz, H-2ʹ, H-6ʹ, Ar); 7.32 (dd, 2H, J = 8.7 Hz, H-3ʹ, H-5ʹ, Ar); 7.55 (br s, 1H, NH); 7.60  
(s, 1H, CH=, 1H). 13C-NMR (CDCl3/TFA 98:2) δ: 22.5 (C-2ʹʹ, C-3ʹʹ); 23.2 (C-3ʹʹ, C-2ʹʹ); 42.5 (C-1ʹʹ,  
C-4ʹʹ); 46.4 (ArCH2NH); 51.9 (C-4ʹʹ, C-1ʹʹ); 101.2 (C-2ʹʹʹ); 108.5 (C-6ʹʹʹ); 108.8 (C-7ʹʹʹ); 116.1 (C-2ʹ, 
C-6ʹ); 118.6 (C-5ʹʹʹ); 121.7 (C=); 123.4 (C-4ʹʹʹ); 125.6 (C-1ʹ); 132.9 (C-3ʹ, C-5ʹ); 134.8 (CH=); 148.0 
(C-7ʹʹʹa); 148.8 (C-3ʹʹʹa); 157.6 (C-4ʹ); 169.0 (C=O, C-4); 192.6 (C=S, C-2). HRMS, m/z: 443.1099 
found (calculated for C22H23N2O4S2 [M + H]+ requires 443.1095). 
(5Z) 3-[4-(1,3-Benzodioxol-5-ylmethylamino)butyl]-5-(4-hydroxy-3-methoxybenzylidene)-2-thioxo-1,3-
thiazolidin-4-one (9k). According to the standard procedure, compound 9k was prepared in 46% yield 
(109 mg) from N-1-benzo[1,3]dioxol-5-ylmethyl-butane-1,4-diamine hydrochloride 6e (129.4 mg,  
0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and 4-hydroxy-3-
methoxybenzaldehyde 3g (76.1 mg, 0.5 mmol, 1 equiv.) after 30 min. at 90 °C, followed by a second 
reaction time of 30 min. at 110 °C (for condensation step with 3g), which gave 9k as a red powder.  
Mp = 200–203 °C. 1H-NMR (CDCl3/TFA 98:2) δ: 1.71 (s, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.05–3.06 (m, 2H, 
ArCH2NH); 3.88 (s, 3H, OCH3); 4.04 (s, 4H, CH2, H-1ʹʹ, H-4ʹʹ); 5.91 (s, 2H, CH2, H-2ʹʹʹ); 6.74 (s, 3H, 
H-4ʹʹʹ, H-6ʹʹʹ, H-7ʹʹʹ, Ar); 6.87–7.02 (m, 3H, H-2ʹ, H-5ʹ, H-6ʹ, Ar); 7.58 (s, 1H, CH=); 7.65 (br s, 1H, 
NH). 13C-NMR (CDCl3/TFA 98:2) δ: 23.1 (C-2ʹʹ, C-3ʹʹ); 23.9 (C-3ʹʹ, C-2ʹʹ); 42.9 (C-1ʹʹ, C-4ʹʹ);  
46.6 (ArCH2NH); 52.1 (C-4ʹʹ, C-1ʹʹ); 56.1 (OCH3); 101.8 (C-2ʹʹʹ); 109.0 (C-6ʹʹʹ); 109.6 (C-7ʹʹʹ); 112.3 
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(C-6ʹ); 115.5 (C-2ʹ); 119.1 (C-5ʹʹʹ); 122.7 (C=); 124.0 (C-5ʹ); 125.8 (C-1ʹ); 126.5 (C-4ʹʹʹ); 134.9 (CH=); 
147.1 (C-3ʹ); 148.6 (C-7ʹʹʹa); 148.8 (C-4ʹ); 149.2 (C-3ʹʹʹa); 168.5 (C=O, C-4); 193.2 (C=S,  
C-2). HRMS, m/z: 473.1205 found (calculated for C23H25N2O5S2 [M + H]+ requires 473.1206). 
(5Z)3-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylamino)butyl]-5-(1,3-benzodioxol-5-ylmethylene)-2-
thioxo-1,3-thiazolidin-4-one (9l). According to the standard procedure, compound 9l was prepared in 
15% yield (36.3 mg) from N-1-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-butane-1,4-diamine 
hydrochloride 6f (136.4 mg, 0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) 
and piperonaldehyde 3e (75.1 mg, 0.5 mmol, 1 equiv.) after 15 min. at 90 °C, followed by a second 
reaction time of 15 min. at 110 °C (for condensation step with 3e), which gave 9l as a yellowish 
powder. Mp = 172–233 °C (decomposition). 1H-NMR (CDCl3/TFA 98:2) δ: 1.66–1.69 (m, 4H, CH2,  
H-2ʹʹ, H-3ʹʹ); 3.03–3.10 (m, 2H, ArCH2NH); 4.03–4.07 (m, 4H, CH2, H-1ʹʹ, H-4ʹʹ); 4.16–4.19 (m, 4H, 
CH2, H-2ʹʹʹ, H-3ʹʹʹ); 5.97 (s, 2H, CH2, H-2ʹ); 6.66–7.00 (m, 6H, H-4ʹ, H-6ʹ, H-7ʹ, H-5ʹʹʹ, H-7ʹʹʹ, H-8ʹʹʹ, 
Ar); 7.55 (br s, 1H, NH); 7.59 (s, 1H, CH=). 13C-NMR (CDCl3/TFA 98:2) δ: 23.8 (C-2ʹʹ, C-3ʹʹ); 24.2 
(C-3ʹʹ); 43.1 (C-1ʹʹ, C-4ʹʹ); 47.0 (ArCH2NH); 52.1 (C-4ʹʹ, C-1ʹʹ); 64.2 (C-2ʹʹʹ); 64.4 (C-3ʹʹʹ); 102.2  
(C-2ʹ); 109.4 (C-7ʹʹʹ); 109.5 (C-8ʹʹʹ); 118.5 (C-5ʹʹʹ); 119.5 (C-6ʹʹʹ); 122.0 (C=); 122.9 (C-6ʹ); 127.3  
(C-5ʹ); 128.2 (C-7ʹ); 135.0 (C-4ʹ); 135.5 (CH=); 143.9 (C-4ʹʹʹa); 145.1 (C-8ʹʹʹa); 150.6 (C-3ʹa); 150.8 
(C-7ʹa); 168.5 (C=O, C-4); 193.0 (C=S, C-2). HRMS, m/z: 485.1205 found (calculated for 
C24H25N2O5S2 [M + H]+ requires 485.1206). 
(5Z)3-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylamino)butyl]-5-(2,3-dihydro-benzo[1,4]dioxin-6-
ylmethylene)-2-thioxo-1,3-thiazolidin-4-one (9m). According to the standard procedure, compound 9m 
was prepared in 7% yield (17.5 mg) from N-1-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-butane-1,4-
diamine hydrochloride 6f (136.4 mg, 0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 
equiv.) and 2,3-dihydro-1,4-benzodioxin-6-carboxaldehyde 3f (82.1 mg, 0.5 mmol, 1 equiv.) after 15 
min. at 90 °C, followed by a second reaction time of 15 min. at 110 °C (for condensation step with 3f), 
which gave 9m as a yellowish powder. Mp = 170–243 °C (decomposition). 1H-NMR (CDCl3/TFA 
98:2) δ: 1.64–1.69 (m, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.04–3.10 (m, 2H, ArCH2NH); 4.03–4.08 (m, 4H, CH2, 
H-1ʹʹ, H-4ʹʹ); 4.16–4.23 (m, 8H, CH2, H-2ʹ, H-3ʹ, H-2ʹʹʹ, H-3ʹʹʹ); 6.75–7.57 (m, 6H, H-5ʹ, H-7ʹ, H-8ʹ,  
H-5ʹʹʹ, H-7ʹʹʹ, H-8ʹʹʹ, Ar); 7.60 (br s, 1H, NH); 8.77 (s, 1H, CH=). 13C-NMR (CDCl3/TFA 98:2) δ: 24.2 
(C-2ʹʹ, C-3ʹʹ); 44.0 (C-1ʹʹ, C-4ʹʹ); 64.2 (C-2ʹ, C-2ʹʹʹ); 64.8 (C-3ʹ, C-3ʹʹʹ); 118.4 (C-7ʹ, C-7ʹʹʹ); 119.6 (C-8ʹ, 
C-8ʹʹʹ); 120.3 (C=); 125.6 (C-5ʹ, C-5ʹʹʹ); 126.8 (C-6ʹ, C-6ʹʹʹ); 134.5 (CH=); 144.0 (C-8ʹa, C-8ʹʹʹa); 146.6 
(C-4ʹa, C-4ʹʹʹa); 166.6 (C=O, C-4); 182.5 (C=S, C-2). HRMS, m/z: 499.1364 found (calculated for 
C25H27N2O5S2 [M + H]+ requires 499.1366). 
(5Z)3-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylamino)butyl]-5-(4-hydroxy-3-methoxybenzylidene)-2-
thioxo-1,3-thiazolidin-4-one (9n). According to the standard procedure, compound 9n was prepared in 34% 
yield (82.7 mg) from N-1-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-butane-1,4-diamine hydrochloride 6f 
(136.4 mg, 0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and 4-hydroxy-3-
methoxybenzaldehyde 3g (76.1 mg, 0.5 mmol, 1 equiv.) after 30 min. at 90 °C, followed by a second 
reaction time of 30 min. at 110 °C (for condensation step with 3g), which gave 9n as a red powder.  
Mp = 202–204 °C. 1H-NMR (CDCl3/TFA 98:2) δ: 1.69 (s, 4H, CH2, H-2ʹʹ, H-3ʹʹ); 3.06 (s, 2H, ArCH2NH); 
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3.86 (s, 3H, OCH3); 4.03 (s, 4H, CH2, H-1ʹʹ, H-4ʹʹ); 4.16 (s, 4H, CH2, H-2ʹʹʹ, H-3ʹʹʹ); 6.67–7.03 (m, 6H, 
H-2ʹ, H-5ʹ, H-6ʹ, H-5ʹʹʹ, H-7ʹʹʹ, H-8ʹʹʹ, Ar); 7.60 (s, 1H, CH=). 13C-NMR (CDCl3/TFA 98:2) δ: 23.1 (C-2ʹʹ 
or 3ʹʹ); 23.8 (C-3ʹʹ ou C-2ʹʹ); 43.1 (C-1ʹʹ ou 4ʹʹ); 47.0 (ArCH2NH); 52.1 (C-4ʹʹ, C-1ʹʹ); 56.1 (OCH3); 
64.4 (C-2ʹʹʹ, C-3ʹʹʹ); 64.4 (C-3ʹʹʹ, C-2ʹʹʹ); 112.6 (C-6ʹ); 115.6 (C-2ʹ); 118.4 (C-7ʹʹʹ); 118.6 (C-8ʹʹʹ); 119.0 
(C-6ʹʹʹ); 122.0 (C=); 122.9 (C-5ʹʹʹ); 125.9 (C-1ʹ); 126.8 (C-5ʹ); 135.9 (CH=); 143.9 (C-8ʹʹʹa); 145.1  
(C-3ʹa); 147.2 (C-4ʹʹʹa); 148.9 (C-4ʹ);169.4 (C=O, C-4); 193.1 (C=S, C-2). HRMS, m/z: 487.1361 found 
(calculated for C24H27N2O5S2 [M + H]+ requires 487.1359). 
3.2. Biochemistry Section 
3.2.1. Protein Kinase Assay Buffers 
Buffer A: 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 µg heparin/mL. 
Buffer B: 60 mM β-glycerophosphate, 15 mM p-nitrophenyl-phosphate, 25 mM Mops (pH 7.2),  
5 mM EGTA, 15 mM MgCl2, 1 mM DTT, 1 mM sodium vanadate, 1 mM phenylphosphate. 
3.2.2. Kinase Preparations and Assays 
Kinase activities for each enzyme were assayed in buffer A (25 mM Tris-HCl pH 7.5, 10 mM MgCl2, 
1 mM EGTA, 1 mM DTT, 50 µg/mL Heparin, BSA 0.15 mg/mL) or B (60 mM β-glycerophosphate,  
30 mM p-Nitrophenylphosphate, 25 mM MOPS, 5 mM EGTA, 15 mM MgCl2, 1 mM DTT, 0.1 mM Na 
vanadate), with their corresponding substrates, in the presence of 15 µM [γ-33P] ATP (3000 Ci/mmol; 
10 mCi/mL) in a final volume of 30 µL. After 30 min incubation at 30 °C, the reaction was stopped by 
harvesting, using a FilterMate harvester (Packard, Meriden, CT, USA), onto P81 phosphocellulose 
papers (GE Healthcare, Velizy-Villacoublay, France) which were washed in 1% phosphoric acid. 
Scintillation fluid was added and the radioactivity measured in a Packard counter. Blank values were 
subtracted and activities calculated as pmoles of phosphate incorporated during the 30 min incubation. 
The activities were expressed in a percentage of the maximal activity, i.e., in the absence of inhibitors. 
Controls were performed with appropriate dilutions of DMSO. CK1 and Haspin peptide substrates 
were obtained from Proteogenix (Oberhausbergen, France). 
CDK5/p25 (human, recombinant) was prepared as previously described [31]. Its kinase activity was 
assayed in buffer B, with 1 mg histone H1/mL. 
Casein kinase 1 (CK1δ/ε) (porcine brain, native) was assayed with 0.67 µg of CKS peptide 
(RRKHAAIGpSAYSITA) [32]. 
GSK-3α/β (porcine brain, native) was assayed, as described for CDK5/p25 but in Buffer A and using a 
GSK-3 specific substrate (GS-1: YRRAAVPPSPSLSRHSSPHQSpEDEEE) (pS stands for phosphorylated 
serine) [33]. GS-1 was synthesized by Millegen (Labege, France). 
Haspin kinase domain (HsHaspin-kd aa 470 to 798) encoding cDNA, obtain by RT-PCR, was cloned 
into pGex-6P-3. The fusion protein was expressed in Escherichia coli strain BL21-KRX (Promega, 
Madison, WI, USA) and purified by affinity chromatography on glutathione-agarose beads (Sigma). 
Haspin-kd activity was assayed with 3 µM Histone H3 (1-21) peptide, a specific Haspin substrate, 
(ARTKQTARKSTGGKAPRKQLA), in Buffer H (MOPS 25 mM pH 7.5; 10 mM MgCl2). 
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3.3. Cell Culture and Survival Assays 
Skin diploid fibroblastic cells were provided by BIOPREDIC International Company (Rennes, France). 
Caco2 (Ref ECACC: 86010202), Huh-7D12 (Ref ECACC: 01042712), MDA-MB-231 (Ref ECACC: 
92020424), HCT-116 (Ref ECACC: 91091005), PC3 (Ref ECACC: 90112714), NCI-H727 (Ref ECACC: 
94060303) cell lines were obtained from the ECACC collection and HaCaT (from Cell Lines Service, 
Eppelheim, Germany). Cells were grown according to ECACC recommendations [34]. The toxicity 
test of the compounds on these cells was as follows: 2 × 103 cells for HCT-116 cells or 4 × 103 for  
the other cells were seeded in 96 multiwell plates in triplicate and left for 24 h for attachment, spreading 
and growing. Then, cells were exposed for 48 h to increasing concentrations of the compounds, ranging 
from 0.1 to 25 μM in a final volume of 120 μL of culture medium. Cells were fixed in cooled solution 
of 90% ethanol/5% acetic acid, nuclei were stained with Hoechst 3342 (Sigma) and counted using 
automated imaging analysis (Cellomics Arrayscan VTI/HCS Reader, Thermo/Scientific, Waltham, MA, 
USA). The IC50 were graphically determined. 
4. Conclusions 
In summary, we have developed, in this preliminary project, a new route to (5Z) 3-(4-arylmethylamino) 
butyl-5-arylidene-2-thioxo-1,3-thiazolidine-4-ones 9. Starting from commercial butane-1,4-diamine, 
the process involved six steps and the key step is a solution phase “one-pot two-steps” approach for the 
construction of the 2-thioxo-1,3-thiazolidine-4-one platform under microwave dielectric heating followed 
by Knoevenagel condensation for installation of the 5-arylidene moiety as second point of diversity. 
This methodology offered the possibility of preparing a library of fourteen new compounds in moderate 
to good yields and, the targeted compounds 9a–n have been built with a Z-geometry. The in vitro 
inhibition of cell proliferation was carried out on a panel of seven representative tumoral cell lines and 
the compounds 9a–n were also evaluated against four protein kinases. Among all of these compounds, 
the compound 9j turned out to be interesting because it presented selective micromolar inhibition activity 
on SsCK1 (IC50 1.4 μM). Molecules 9h and 9i were also bioactive on SsCK1 and HsCDK5-p25. The 
current results are the starting point of a new larger program within our group to investigate intensively 
the biological properties of these new inhibitors with potential application in Alzheimer’s disease or  
in cancer. 
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